Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

Next Previous
Trial Profile

A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD19 Chimeric Antigen Receptor T cell therapy Takara Bio (Primary) ; Cyclophosphamide
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TBI-1501
  • Sponsors Otsuka Pharmaceutical; Takara Bio

    • Most Recent Events

    • 15 Jun 2022 Status changed from recruiting to active, no longer recruiting.
    • 09 Nov 2021 According to an Otsuka Pharmaceutical media release, under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.
    • 09 Nov 2021 According to an Otsuka Pharmaceutical media release, the company has decided jointly with Takara Bio Inc, to terminate agreements on co-development and exclusive marketing of CD19-targeted CAR gene therapies (TBI-1501). In consideration of the lengthy period for clinical development and the competitive landscape, the two companies have decided to terminate the agreement.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top